Maple Rock Capital Partners Inc. Buys 3,235,100 Shares of Bausch Health Companies Inc. (NYSE:BHC)

Maple Rock Capital Partners Inc. increased its position in Bausch Health Companies Inc. (NYSE:BHC - Free Report) by 156.7% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 5,300,000 shares of the company's stock after buying an additional 3,235,100 shares during the period. Bausch Health Companies accounts for 1.3% of Maple Rock Capital Partners Inc.'s portfolio, making the stock its 13th largest holding. Maple Rock Capital Partners Inc. owned 1.47% of Bausch Health Companies worth $42,718,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Mountain Hill Investment Partners Corp. acquired a new position in shares of Bausch Health Companies during the 4th quarter valued at about $56,000. Bank of Nova Scotia acquired a new position in Bausch Health Companies during the fourth quarter valued at approximately $83,000. One68 Global Capital LLC bought a new position in shares of Bausch Health Companies in the fourth quarter valued at approximately $90,000. Alpine Global Management LLC bought a new stake in shares of Bausch Health Companies during the 4th quarter worth $114,000. Finally, Tobam grew its stake in Bausch Health Companies by 10.4% in the 4th quarter. Tobam now owns 15,034 shares of the company's stock valued at $121,000 after buying an additional 1,422 shares during the last quarter. Institutional investors own 78.65% of the company's stock.

Bausch Health Companies Trading Up 2.2 %

BHC stock traded up $0.12 during trading on Friday, reaching $5.42. 2,045,265 shares of the stock were exchanged, compared to its average volume of 2,682,008. Bausch Health Companies Inc. has a twelve month low of $3.96 and a twelve month high of $9.85. The company has a market capitalization of $2.00 billion, a P/E ratio of -45.12, a price-to-earnings-growth ratio of 0.37 and a beta of 0.34. The stock has a 50 day simple moving average of $6.06 and a 200-day simple moving average of $7.21.

Bausch Health Companies (NYSE:BHC - Get Free Report) last announced its quarterly earnings data on Wednesday, February 19th. The company reported $1.21 earnings per share for the quarter, missing the consensus estimate of $1.65 by ($0.44). The firm had revenue of $2.56 billion for the quarter, compared to analyst estimates of $2.51 billion. Bausch Health Companies had a negative return on equity of 577.82% and a negative net margin of 0.48%. Equities analysts predict that Bausch Health Companies Inc. will post 4.41 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. StockNews.com raised shares of Bausch Health Companies from a "hold" rating to a "buy" rating in a research report on Thursday. Royal Bank of Canada increased their target price on Bausch Health Companies from $8.50 to $10.00 and gave the company a "sector perform" rating in a research note on Friday. Finally, Jefferies Financial Group reaffirmed a "hold" rating and issued a $8.00 price target (down from $12.00) on shares of Bausch Health Companies in a research report on Thursday, February 6th. One analyst has rated the stock with a sell rating, six have given a hold rating and one has issued a buy rating to the company. According to MarketBeat, Bausch Health Companies presently has a consensus rating of "Hold" and an average price target of $7.42.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.